The pharmaceutical marketplace has changed dramatically over the last few years as pharmaceutical companies are moving from centralized, internal production to single-source providers or Contract Manufacturing Organizations (CMO).
TJCY contains other products and information you need, so please check it out.
The principal reason behind this evolution in the landscape is simple, to cut costs, increase capacity and reduce time-to-market. Beyond these obvious criteria, there are numerous other reasons why pharmaceutical companies are relying heavily on the growing CMO market.
Whereas CMOs once produced primary packaging they now offer a multitude of services from design and discovery to final packaging.
Outsourcing to a CMO allows the pharmaceutical company to add technical resources without increasing its overhead costs. The result of this is that the pharmaceutical company does not need to invest in expanding its staff and manufacturing facilities, to add new varieties of medicines into its product lines.
Pharmaceutical companies can now concentrate on core products regarding R&D and production and leave their secondary and tertiary products to the CMO.
The term CMO can refer to a multitude of different companies including Contract Packaging Organizations, and Contract Pharmaceutical Manufacturers. However, in recent years CMOs have been more or less classified into two types of organizations:
These are companies that manufacture a substance(s) that are used as a component of a finished drug.
These are companies that provide a drug product for administration to a patient without the need for substantial further manufacturing and often in its final packaged form. The CMO market is currently divided almost equally between API manufacturers and FDF manufacturers.
Within FDF contract manufacturing, solid dose compounds currently dominate the market. However, future growth is likely to be driven by injectables dose manufacturing primarily due to an increased focus on complex disease areas and the growing trend of self-administration.
Regarding market growth and potential future growth, the CMO channel is a force to reckon with.
For North America, Europe, and Japan in the last years, the CMO market grew at close to three times the rate of the pharmaceutical market: 8% versus 3%.
(It is important to note that the 3% growth is for the pharmaceutical market as a whole, top Pharmaceutical companies have grown significantly faster at a rate average of over 11%. It is also important to note that most large pharmaceutical companies have divisions operating as CMO)
Over the next decade years, the CMO market is expected to continue to grow at an annual rate of 6% to 9%, with annual revenues currently valued at between 25-30 billion dollars. This growth will be further fueled by new opportunities within the generic drug market.
Although the CMO seems to be poised to become a major player in the pharmaceutical marketplace several challenges await.
The trend is already apparent as saw a glut of companies and manufacturing facilities being bought and sold.
Smaller pharmaceutical companies use the services of CMOs significantly more than large pharmaceutical companies. The challenge lies in that the growth opportunities are a lot smaller.
Want more information on fdf pharma? Feel free to contact us.
With lower capital costs many pharmaceutical companies are rethinking the CMO route for moving back to traditional centralized production.
As with any part of the pharmaceutical landscape, the role of the CMO will follow a predictable route. Larger ones will absorb the smaller CMOs, and the large CMOs will come forward to be the only players to be able to support the large Pharmaceutical and Biopharmaceutical companies.
New channels will open within the generic pharmaceutical marketplace fostering further growth for the large CMO.
GlobalVision is the leading developer of proofreading technologies for the FDF Contract Manufacturer market. All our quality control solutions meet FDA 21 CFR Part 11 / EMA Annex 11 requirements.
For more information on GlobalVision and the Quality Control Platform for CMOs, please visit: globalvision.co or :
A finished dosage form (FDF) describes the consumable, finalized drug product - tablets, pills, liquid solutions, and other forms of FDFs all come under this category. However, all FDFs include an API along with other inactive components.
The two main parts of any pharmaceutical product are the active pharmaceutical ingredient (API) and the excipient (additional chemicals used to aid in the drug's delivery). Chemically inert fillers like lactose or cellulose derivatives would be some examples of the excipients
To put simply, APIs form the crux of the finished dosage form - the main ingredient that’s meant to meet the objectives of the prescription.
Each drug's (API) strength is measured against industry standards during production. However, there might be significant variations in quality across different manufacturers. The testing procedures used by each manufacturer can cause substantial variations in product efficacy.
The FDA requires manufacturers to demonstrate their medications' efficacy in laboratory settings and clinical trials involving actual patients.
APIs are often manufactured in the home countries of pharmaceutical corporations. However, in recent years, many businesses have elected to outsource production to countries with lower labor costs. Because of this, stricter criteria and inspections have been implemented to regulate these medications.
Although numerous pharmaceutical businesses can be found in the United States and the United Kingdom, most API manufacturers are located outside these countries. The most populous ones can be found in Asia, especially in China and India.
In order to save money on resources like staff and building maintenance, an increasing number of businesses are outsourcing. Despite the positive impact on their bottom line, there remains persistent worry about the quality of APIs in foreign countries.
The efficacy (achieving the desired effect) and the safety of drugs are significantly impacted by the quality of their active pharmaceutical ingredients. Substandard or degraded APIs have been linked to major health problems and fatalities.
APIs are still subject to the country of destination's strict regulations and oversight, even in the case of outsourcing. For instance, the U.S. Food and Drug Administration still inspects foreign API factories.
The development of APIs indicates the dynamic nature of the pharmaceutical sector. Today, pharmaceutical manufacturing is a more decentralized process. Before, the API, capsule, and packaging were all made and distributed by the same company.
The regulatory agencies charged with ensuring the public's safety have responded by instituting stringent checks on all pharmaceuticals. A violation of these defined rules may result in fines or a highly costly recall for the pharmaceutical firms backing these businesses.
According to a recent industry study, injectable Finished Dosage Forms are expected to dominate the market from to , where APIs accounted for the greatest market share in . Growth in this sector is anticipated to be propelled by factors like the growing demand for innovative and generic medicine formulations.
Revenue from generic API manufacturing was the largest in and is projected to increase as patents on branded medications expire, and generic drugs become more affordable.
In spite of their conceptual differences,Finished Dosage Forms and APIs are inseparable when it comes to the research, development, and manufacturing of novel formulations and drug delivery methods
ZIM Labs is an innovative drug delivery solution provider focusing on improving patient convenience and adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for the production and supply of innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs we provide our customers a comprehensive range of value-added solid dosage differentiated generic products in semi-finished and finished categories/formulations. These include granules, pellets(immediate, sustained, modified and extended-release), taste-masked powders, suspensions, tablets, capsules, and recently developed Oral Thin Films (OTF).
If you are looking for more details, kindly visit pharmaceutical formulation intermediates.